Fondaparinux: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
===Arixtra<sup>®</sup>=== | |||
'''| [[Fondaparinux indications and usage|Indications and Usage]]''' | '''| [[Fondaparinux indications and usage|Indications and Usage]]''' | ||
'''| [[Fondaparinux dosage and administration|Dosage and Administration]]''' | '''| [[Fondaparinux dosage and administration|Dosage and Administration]]''' | ||
Revision as of 19:14, 3 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
For patient information, click here. Synonyms / Brand Names: Arixtra®
Overview
Category
FDA Package Insert
Arixtra®
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages